Jared Kaltwasser

The research raises the possibility that the type of therapy used can increase the risk of tumor lysis syndrome from low to moderate in men with multiple myeloma (MM).

A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).

The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.

The new data provide hope that the therapy will prove effective for a patient group with limited options.

Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.

A new dose-finding study found a twice-daily 200 mg dose of the JAK2/IRAK1 inhibitor pacrinitib led to a spleen volume response in nearly 1 in 10 patients.

Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.

New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.

The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.

The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.

The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.

Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.

A new report finds including rituximab in first-line therapy for diffuse large B-cell lymphoma (DLBCL) results in better overall outcomes that more than offset the higher initial cost of therapy.

The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).

New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma.

The risk of leukemia is higher for people living near petroleum industry complexes, according to a new analysis of 13 studies of the issue.

Chimeric antigen receptor (CAR) T cells can be highly effective, but the durability of the therapy has been lacking in many patients with hematological malignancies. Many efforts are underway to fix this problem.

New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.

In what is believed to be the first study of its kind, investigators found patients with leukemia face a higher risk of suicide than the general public, especially if they had acute myeloid leukemia.

Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally successful.

A new study suggests a potential new marker that could be used to track response to therapy and disease progression in patients with multiple myeloma.

Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.

There did not appear to be any particular patient characteristics linked with best responses to carfilzomib in patients with multiple myeloma, with the exception of low serum lactate dehydrogenase.

Up until now, it was thought most patients with hemophilia A developed inhibitors in middle-age. A new study suggests it usually happens in the early teens.

Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.

Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.

A 72-year-old patient with Burkitt lymphoma was successfully treated with nivolumab after standard-of-care chemotherapy failed.

New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.

Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.

T-cell prolymphocytic leukemia is rare and shares many features with other conditions. A new review article helps explain some of the tactics physicians can use to correctly identify it.